Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ESRRB | O95718 | 6/20 | 0.47 |
| ▸ | ESRRA | P11474 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577530 | 1.00 | MAOA (0.49) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL6122887 | 0.91 | ESRRB (0.45) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL31253972 | 0.89 | ALDH1A1 (0.61) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL11850245 | 0.89 | ALDH1A1 (0.61) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL29347736 | 0.88 | MAPK14 (0.48) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL31411939 | 0.87 | MAOA (0.45) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL31408196 | 0.87 | ALDH1A1 (0.59) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL802622 | 0.84 | MAOB (0.57) | MAOBMIFALDH1A1MAPTRAB9A | |
| SCHEMBL3198655 | 0.83 | ALDH1A1 (0.41) | MAOAMAOBMIFALDH1A1MAPT | |
| SCHEMBL23111392 | 0.81 | ESRRB (0.40) | MAOAMAOBMIFALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4330245-B1 | N-ALKYL-O-ARYL CARBAMATES OF 6H-DIBENZO[]B,D]PYRAN-3,8-DIOLS AS MITOPHAGY ENHANCERS | Floratek Pharma SA (CH) | 2026-02-04 | — | — | EP | disclosed |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12377069-B2 | Compounds, compositions, methods of using, and methods for preparing compounds | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| EP-4561556-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024236367-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| CN-112638889-A | Urolithin A and derivatives thereof for use in therapy | 路易斯维尔大学研究基金会 | 2021-04-09 | — | — | CN | disclosed |
| EP-3793984-A1 | UROLITHIN A AND DERIVATIVES THEREOF FOR USE IN THERAPY | University Of Louisville Research Foundation, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-9096795-B2 | Liquid crystal display | MERCK PATENT GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096795-B2 | Liquid crystal display | MERCK PATENT GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2432851-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2013-10-02 | — | — | EP | disclosed |
| EP-2432851-A1 | LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010133278-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133278-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | MAOA 1636/4885MAOB 1315/4885MIF 3386/4885 |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAOA 699/4885MAOB 590/4885MIF 4270/4885 |
| US-12377069-B2 | Compounds, compositions, methods of using, and methods for preparing compounds | UTS2R, REN, UMPS | MAOA 276/4885MAOB 326/4885MIF 1571/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAOA 699/4885MAOB 590/4885MIF 4270/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAOA 699/4885MAOB 590/4885MIF 4270/4885 |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | LPXN, VCL, ACP3 | MAOA 2468/4885MAOB 2889/4885MIF 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.